NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Yescarta® (Axicabtagene Ciloleucel) or Post-Breyanzi® (Lisocabtagene Maraleucel) in Subjects With Relapsed/Refractory Large B-cell Lymphoma

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

April 30, 2028

Conditions

Large B-cell Lymphoma

Interventions

DRUG

NT-I7

Provided by NeoImmune Tech

BIOLOGICAL

CAR T-cell therapy

Will be given on day 0

Trial Locations (1)

Washington University School of Medicine, St Louis